NCT00512785View on ClinicalTrials.gov

Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder

PHASE3CompletedINTERVENTIONAL
Enrollment

435

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

May 31, 2009

Conditions
Overactive Bladder
Interventions
DRUG

imidafenacin, KRP-197/ONO-8025

0.1 mg BID for 52 weeks

DRUG

imidafenacin, KRP-197/ONO-8025

0.1 mg BID for 12 weeks and 0.2 mg BID for 52 weeks

Trial Locations (2)

Unknown

Kanto Region, Kanto

Kinki Region, Kinki

Sponsors
All Listed Sponsors
collaborator

Kyorin Pharmaceutical Co.,Ltd

INDUSTRY

lead

Ono Pharmaceutical Co. Ltd

INDUSTRY